Sample. Virtus Health Ltd. Financial Analysis VRT $7.15. No Holding at Time of Report
|
|
- Diane Newton
- 5 years ago
- Views:
Transcription
1 Virtus Health Ltd Financial Analysis Date: VRT $7.15 Disclosure: Contact: W: E: T: Jul-213 No Holding at Time of Report
2 VRT Overview Virtus Health (VRT) is a leading provider of reproductive health services, primarily IVF cycles. The business also operates diagnostic labs and day hospital facilities that are used in conjunction with these services. The business was formed through the merger in of three state based fertility businesses: - IVF Australia (NSW); - Melbourne IVF (Vic); and - Queensland Fertility Group The merger was undertaken with Quadrant Private Equity, who sold their 46% stake in an IPO in June 213. VRT - Divisional Sales Specialised Diagnostics 8% Assisted Reproductive Services 79% Day Hospital 13% 2
3 VRT Profit History Since merging, the combined group has delivered strong growth in sales and profits. As a private equity structure, NPAT has been impacted by funding structures. VRT - Sales VRT - Operating Earnings EBITDA EBIT VRT - Profit Trends (211 = 1) 2 Sales EBIT NPAT EPS (Adj.) 15 DPS (Adj.)
4 VRT Profit Drivers Although the statutory numbers have been boosted by the roll up, organic growth has been strong VRT - Sales Statutory Pro-Forma Although new Dr s are not as productive initially, revenue momentum has been sustained by higher prices. VRT - Revenue IVF Cycles/Specialist Avg. Rev./IVF Cycle 15, 12, 9, driven by the higher number of reproductive specialists contracted to the group. VRT - Ave. Specialists Contracted As an aside, it is worth noting the seasonality in the business due to the impact of holidays on H2 volumes. VRT - HY Earnings 3 2 EBIT Sales , , H1 12 H2 12 H1 13 H2 13 4
5 VRT Earnings Quality Earnings quality is good, with no major issues. VRT - Free Cash Flow Excellent cash generation Free Cash Flow NPAT (Pre GW) and very strong operating cash conversion VRT - GOCF/EBITDA is a function of minimal capex requirements 12 VRT - Capex/Depreciation % 1% 5% Total Capex Depreciation due to the negative working capital model of the business. VRT - Working Cap./Sales Inventory Receivables Payables Net Working Capital 2 % EBITDA GOCF -5% %
6 VRT Group Returns This combination of: - negative working capital; - minimal fixed asset investment; and - Goodwill which is purely a function of the historic roll up means organic investment in the business is minimal. Therefore, returns are driven entirely by margins and if revenue growth can be delivered, incremental returns are exceptional. VRT - Investment/Sales 3% 2% 1% % -1% 4% 3% 2% 1% % Fixed Assets Intangibles Net Working Capital VRT - Margins EBIT Margin EBITDA Margin EBITDAR Margin 8% 6% 4% VRT - ROFE Incremental Funds Total Funds 2% %
7 VRT Divisional Returns At first glance, the stability of the various cost lines for the business suggests that current margins are maintainable. VRT - Cost/Sales 4% 3% 2% 1% % Occupancy Employee Benefits Advertising & Marketing Other However, there are three risks: - Firstly, are potential funding changes. Although out of pocket expenses are already high (25-5%), potential cuts in funding (including the recent increase in the EMSN cap) have the potential to impact both volumes and mix of higher revenue customers. - The introduction of the EMSN cap in 21 saw 1% volume declines, which highlights the second risk, being any potential leverage to the economic cycle. VRT - Cost/Sales 2% 15% 1% 5% % 15, 12, 9, 6, 3, Provider Consumables Associated VRT - IVF Cycle Funding Breakdown First Cycle - Basic First Cycle - Advanced Out of Pocket Private Health Gv't (EMSN) Gv't (MBS) Second Cycle - Basic However, both these risks are likely to be only short term in their impact. Second Cycle - Advanced By far the biggest issue for margins is the sustainability of current pricing arrangements with the specialist providers. Provider fees currently represent ~16% of sales. With profits at 25% of sales, is there a risk that over time the Dr s will look to increase their share of the pie? 7
8 VRT Comparative Returns Certainly, margins look very high relative to other professional services healthcare businesses. The two most important case studies here are Vision Group and the radiology sector where after selling their businesses, the Dr s eventually reclaimed a large share of the pie. Note the radiology sector in particular has much greater capital requirements and potential scale benefits, yet still only commands sub 15% margins. Note that to the extent that the higher margins are caused by the 2% of VRT sales from diagnostics and day care facilities, this would also appear to be a case of overearning. Neither the pathology or hospital operators command margins >2% despite the much greater scale benefits in pathology and much greater asset intensity in Hospitals. Healthcare Prof. Services - EBIT Margins 4% 2% % 25% 2% 15% 1% 5% VRT GXL VEI SHL - Radiology PRY - Radiology Aus. Pathology - EBIT Margin SHL PRY % Healthscope Symbion Gribbles -5% Hospitals - EBIT Margin 2% 15% 1% Healthscope Ramsay Mayne Nova Alpha 5% 8 Source: Company Reports %
9 VRT Industry Case Study Nevertheless, VRT s margins are consistent with peers: - Healthbridge Formed by the merger of Repromed and Monash IVF; - Genea, (owned by 17 Dr s and staff). However, margins of the precursor businesses of these groups show much more variability. IVF Aus & Qld Fert were precursors of VRT, and the margin profile of the latter prior to Virtus ownership raises some concerns. Prior to private equity ownership, the owners of these businesses could chose to take their earnings in either wages or dividends. If we restate margins including dividends as a cost of sales, then the transformation from private ownership to private equity is stark. In essence the Dr s have swapped their salary for an upfront payment via the sale of their businesses to private equity and the public market. Reproductive Services - EBIT Margins 4% 3% 2% 1% % 5% 4% 3% 2% 1% % Virtus Health Healthbridge Genea - IVF Reproductive Services - EBIT Margins IVF Australia QLD Fertility Group Monash IVF Repromed 45% 3% 15% Reproductive Services - EBIT Margins Adj. for Dividends IVF Australia QLD Fertility Group Monash IVF Repromed Genea A good trade for the current Dr s but what of the next generation who can no longer participate in equity ownership? 9 % -15%
10 VRT Dr Employment Whilst there is a strong likelihood that over time Dr s will demand a much higher share of the revenue pool, in the short term this is mitigated by the duration of employment contracts and share escrow periods. Initial contract terms are for 5 years. With the majority of Dr s contracted pre FY 1, this five year period will be rolling off. Note 5 pre FY 1 Dr s have already retired. VRT - Specialists Contracted FY 13 FY 12 FY 11 FY 1 Pre FY % of pre-listing shares are escrowed for specialists (i.e. ~13m shares). Terms of escrow release are: - 3% in each year post listing; - 2% at age 63 (or two years post listing if Dr is, or will turn, 63 in this period); - 2% at retirement. Furthermore, Dr s may retire after age 61 without any impact on their share escrow arrangements. 3% of Dr s (who perform 43% of the volume) are >55 yrs of age. VRT - Age Profile of Specialists < >63 37% 18% 32% VRT - Share Ownership Prior Shares 13% Post Fertility Specialists Scientists 1..6 Mgmt/Staff 1..7 Quadrant Funds Other Existing New Total Source: Company Reports 1
11 VRT Balance Sheet VRT will list with a balance sheet that is fully geared, given there are essentially no tangible assets in the business. (note net debt for total VRT group prior to listing was ~$2m chart reflects statutory accounts). This is justified on the current earnings of the group, with interest cover at 5x and fixed charges cover >3x. However, this relies on the current margins of the group being maintained. Viewed as net debt/sales (i.e normalising for margin), VRT s debt levels are the highest in the sector. Therefore, whilst at current levels of earnings and cash generation, debt service obligations and dividend payout (~65% target) are ok, there is little flexibility should margins come under pressure. VRT - Net Assets VRT - Debt Coverage Fixed Charges Cover (EBITx) Interest Cover (EBITx) Interest Cover (EBITDAx) Other LT Assets Intangibles Net Curr. Assets Fixed Assets Net Debt Source Healthcare Prof. Services - Net Debt/Sales VRT VEI PRY GXL SHL
12 VRT Valuation On earnings metrics, VRT is priced for solid medium term growth with a high teens PER. And low teens EBIT multiple on a fully geared balance sheet. More concerning is the >3x multiple of forward sales, which implies both revenue growth and current margins are achievable. VRT - PER VRT - EV/Earnings EV/EBITA EV/EBITDA VRT - EV/Sales
13 VRT Comparative Valuation Whilst VRT s earnings multiples are comparable to others in the sector Healthcare Professional Services EV/EBITA VRT GXL VEI SHL PRY CAJ Source: Bloomberg.. It is by far and away the most expensive stock in the sector on a multiple of sales. Healthcare Professional Services EV/Sales VRT GXL VEI SHL PRY CAJ Source: Bloomberg 13
14 VRT Conclusion VRT has a solid position in the reproductive health industry. The industry itself has some favourable demographic characteristics that support top line growth. In the short term, there are some potential risks to volume from a slowing economy and limited ability to exercise any pricing power given extent of recent price increases and impact of reduced Medicare funding. However, by far and away the biggest issue is the sustainability of group margins as the current arrangements with Dr s roll off over the next few years. Margins are well above comparable professional health services businesses. Compounding this, the balance sheet has been geared to reflect current margins, and valuations are capitalising current earnings at low teens EBIT multiples. None of this suggests an attractive risk/reward proposition. 14
15 Disclaimer Use of this Document is restricted to wholesale clients who are subscribers to the Services and is subject to the information below. Diogenes Research [213] This Document (and any verbal presentation we give in relation to it) is provided by Diogenes Research Pty Ltd ACN AFSL No (Pup Research is a registered business name of Diogenes Research Pty Ltd). This Document is subject to the Terms of Use, Privacy Policy and Disclosures on our website: This Document is subject to copyright. No part of this Document may be shown, distributed or otherwise published or communicated to third parties or reproduced or transmitted in any form or by any means without prior written consent of the copyright owner. Any financial product advice in this Document is general advice intended for wholesale clients as defined in section 761G of the Corporations Act 21 (Cth) who subscribe to the Services and does not take into account the objectives, financial situation or needs of any person. It is not intended for retail clients or nonsubscribers. You must not rely on any general advice in this Document to make an investment decision without considering its appropriateness in your own circumstances. Past performance is not an indicator of future performance. No guarantee is given of the performance of any securities. All investments carry risk and may not perform as well as expected. The price of shares and other securities can fall as well as rise and investors may lose their capital and may not receive anticipated income. All information provided in this Document is given in good faith by one or more of Pup Research, Diogenes Research, their respective related bodies corporate, shareholders, officers, employees, representatives, agents, advisers, contractors or consultants including third party research providers (collectively 'we', 'us' or 'our'). All factually based or historic information in this Document has been sourced from publicly available information that we believe to be reliable at the date of publication without having sought to verify the information. All other information in this Document reflects, as applicable, our opinions, beliefs, expectations, recommendations, conclusions, analysis, results of analysis, estimates or illustrations or other views (including as to future matters) where relevant in reliance on the factually based or historic information. Any information as to future matters is indicative only and must not be taken as a prediction, promise, representation or guarantee of such matters as the information may differ materially from the actual circumstances that occur in the future as a consequence of known or unknown risks and uncertainties or the inaccuracy of information relied on (including, in the case of tools for a user to generate information, inputs by the user proving to be inaccurate), any assumptions made or methodologies used. To the maximum extent permitted by law: (a) no express or implied representation is made or warranty given by any of us as to the contents of this Document being free from viruses, or as to the accuracy, reliability, currency or completeness or the suitability or ability to predict the future of any information; (b) we disclaim all liability (including liability arising from negligence) for any direct or indirect loss, damage, cost or expense whatsoever which may be suffered by any person who receives this Document or who relies on anything contained in or omitted from this Document; and (c) we accept no responsibility to update any person regarding any inaccuracy, omission or change in any such information included in this Document nor any obligation to furnish the person with any further information. 15
Interim FY 2015 results 6 months ended 31 December February 2015
Interim FY 2015 results 31 December 2014 18 February 2015 Highlights Solid trading result for 1H FY2015; change in accounting policy for acquisition of healthcare practices First half result highlights
More informationHALF YEAR RESULTS PRESENTATION SIX MONTHS ENDED 31 DECEMBER FEBRUARY 2015
HALF YEAR RESULTS PRESENTATION SIX MONTHS ENDED 31 DECEMBER 2014 25 FEBRUARY 2015 DISCLAIMER The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) ( MVF ) (including its subsidiaries,
More informationFor personal use only
Affinity Education Group Full Year 2014 Results 27 February 2015 2014 Highlights FY 2014 Earnings Growth Underlying EBITDA of $17.9m (1) and underlying NPAT of $11.4m (1) Underlying EPS of 8.1 cents (1)
More informationFINANCIAL RESULTS PRESENTATION H1FY18
Virtus Health (ASX:VRT) FINANCIAL RESULTS PRESENTATION H1FY18 Tuesday 20 th February, 2018 9.15am AEDT DISCLAIMER The material in this presentation has been prepared by Virtus Health Limited ABN 80 129
More informationFINANCIAL RESULTS PRESENTATION FY2018
Virtus Health (ASX:VRT) FINANCIAL RESULTS PRESENTATION FY2018 Tuesday 21 August, 2018 AEST DISCLAIMER The material in this presentation has been prepared by Virtus Health Limited ABN 80 129 643 492 ( Virtus
More informationFY17 RESULTS. Tuesday 20 February 2018
FY17 RESULTS Tuesday 20 February 2018 Agenda 2017 Highlights Results 2018 Observations Out-of-Home industry APN Outdoor Contract renewals Focus and objectives Trading update 2 2017 Highlights 3 2017 highlights
More informationLIFE STARTS HERE. FY18 Full Year Results Presentation. 27 August 2018
LIFE STARTS HERE FY18 Full Year Results Presentation 27 August 2018 Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) ( MVF ) (including its subsidiaries, affiliates
More information2011 Interim Results. Keith Gordon, Managing Director & Chief Executive Officer Stephen Gobby, Chief Financial Officer
2011 Interim Results Keith Gordon, Managing Director & Chief Executive Officer Stephen Gobby, Chief Financial Officer Emeco 2011 Interim Results Overview Financials Strategy & Outlook Questions Appendices
More informationMonash IVF Group. FY16 Results Presentation 26 August 2016
Monash IVF Group FY16 Results Presentation 26 August 2016 Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) ( MVF ) (including its subsidiaries, affiliates and
More information1H18 RESULTS 6 MONTHS ENDED 31 DECEMBER 2017
1H18 RESULTS 6 MONTHS ENDED 31 DECEMBER 2017 GROUP RESULTS 2 GROWTH IN PROFIT AND FCF Group Underlying 1 Reported 2 1H 2018 1H 2017 1H 2018 1H 2017 Revenue 856.5 808.7 856.5 808.7 EBIT 81.3 81.9 61.6 61.1
More informationPraemium (PPS) COMPANY REPORT. Model performance
14 August 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $0.58 Share Price $0.41 SNAPSHOT Monthly Turnover $9.5mn Market Cap $165mn Shares Issued 398.5mn 52-Week High $0.54 52-Week
More informationVIRTUS HEALTH (ASX: VRT) FINANCIAL RESULTS PRESENTATION FY2017
VIRTUS HEALTH (ASX: VRT) FINANCIAL RESULTS PRESENTATION FY2017 Tuesday 22 nd August, 2017 AEST DISCLAIMER The material in this presentation has been prepared by Virtus Health Limited ABN 80 129 643 492
More informationAn Integrated Financial Services Company
An Integrated Financial Services Company Investor Presentation 22 November 2016 Disclaimer This document has been prepared by Sequoia Financial Group Limited, ACN 091 744 884 ( Company, we or us ). Information
More informationWisr Ltd (DirectMoney)
Wisr Ltd (DirectMoney) Strategic placement at 56% premium to previous close Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace lending sector. The
More informationWisr Ltd (DirectMoney)
Wisr Ltd (DirectMoney) Interim result draws a line in the sand Wisr Limited (WZR.AX) is an online consumer lending platform competing in the rapidly growing marketplace-lending sector. The company has
More informationANNUAL GENERAL MEETING
Virtus Health (ASX. VRT) ANNUAL GENERAL MEETING Wednesday 22nd November 2017 2.00pm AEDT DISCLAIMER The material in this presentation has been prepared by Virtus Health Limited ABN 80 129 643 492 ( Virtus
More informationRegional Express Holdings Ltd REX
20 February 2006 REX $1.15 Analyst Ken Fleming (613) 6224 8511 ken.fleming@tricom.com.au Max Wheeler (613) 6224 9899 Fully diluted shares on issue 115.0M Market cap A$132.3M Performance & Valuation Last
More informationINVESTOR PRESENTATION
HEALTHCARE LIMITED (ASX: ZNT) INVESTOR PRESENTATION NEXTT HOME CARE TRANSACTION 3 JULY 2017 Important Notice and Disclaimer The information contained in this presentation has been prepared by Zenitas Healthcare
More informationFull Year 2017 Results Presentation Bravura Solutions Limited
Full Year 2017 Results Presentation Bravura Solutions Limited 23 rd August 2017 Important notice and disclaimer The information contained in this document (including this notice) or discussed at this presentation
More informationSigma Pharmaceuticals Limited
Investor Relations Contact: Gary Woodford Corporate Affairs Manager Gary.Woodford@signet.com.au Phone: 03 9215 9632 Mobile: 0417 399 204 Mark Hooper CEO and Managing Director Gary Woodford Corporate Affairs
More informationJackpotJoy plc. A transformational year. Revenue and EBITDA slightly ahead of estimates. Strong operating cash flow dividends from 2019
JackpotJoy plc A transformational year FY17 results Travel & leisure 2017 was a transformational year for JPJ, with a successful London listing followed by substantial improvements in the capital structure.
More informationFreedom Insurance (FIG)
03 November 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk Medium Price Target $0.85 Share Price $0.50 SNAPSHOT Monthly Turnover $13.0mn Market Cap $169mn Shares Issued 239.7mn 52-Week High $0.97 52-Week
More informationSG Fleet Group. Another UK acquisition. Earnings and target price revision
AUSTRALIA SGF AU Price (at 08:26, 30 Nov 2016 GMT) Outperform A$3.23 Valuation - PER A$ 3.96-4.22 12-month target A$ 4.37 12-month TSR % +41.0 Volatility Index High GICS sector Commercial & Professional
More informationFor personal use only
HEALTHSCOPE LODGES PROSPECTUS AHEAD OF INITIAL PUBLIC OFFERING 30 June 2014 Pty Limited (to be renamed (Healthscope) announced today it (together with Healthscope SaleCo Limited (SaleCo)) has lodged a
More informationGROUP RESULTS FY17 RESULTS
CLICK FY 2017 TO EDIT RESULTS MASTER TITLE YEAR ENDED 30 JUNE STYLE 2017 GROUP RESULTS 2 FINANCIAL HIGHLIGHTS Group Underlying 1 Reported FY 2017 FY 2016 FY 2017 FY 2016 Revenue 1,658.6 1,618.5 1,658.6
More informationISRA VISION Neutral
Update Note Closing price as of 1/8/17: 142.8 4 September 217 Company / Sector Fair Value Recommendation ISRA VISION 128. Neutral Technology: Machine Vision ( 128.) (unchanged) Solid Q3 leaves company
More informationPraemium (PPS) COMPANY REPORT. Quartermaster
10 October 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $0.58 Share Price $0.45 SNAPSHOT Monthly Turnover $9.2mn Market Cap $162mn Shares Issued 399.6mn 52-Week High $0.54 52-Week
More informationQV Equities Limited. Investor Update - 1 -
QV Equities Limited Investor Update - 1 - March roadshow 2015 QV Equities Limited Intro & Business Update Managed by Investors Mutual Focused on Ex-20 stocks Listed 22 August 2014 Quality and experienced
More informationH1 FY15 Results Presentation
H1 FY15 Results Presentation 10 February 2015 Andrew Grech Group Managing Director Wayne Brown CFO Ken Fowlie CEO Australia 1 Disclaimer This document has been prepared by Slater and Gordon Limited (Slater
More informationFor personal use only 1H 2016 RESULTS 6 M O N T H S E N D E D 3 1 D E C E M B E R
1H 2016 RESULTS 6 M O N T H S E N D E D 3 1 D E C E M B E R 2 0 1 5 17 FEBRUARY 2016 OVERVIEW 1H 2016 Underlying result in line with expectations Reported results strong supported by one-offs Strengthened
More informationFY18 Results Presentation Bravura Solutions Limited. 28 August 2018
FY18 Results Presentation Bravura Solutions Limited 28 August 2018 Important notice and disclaimer The information contained in this document (including this notice) and discussed at this presentation
More informationGear4music Holdings. Market share gains and margin boost. Strong pre-christmas trading. FY18 forecast maintained
Gear4music Holdings Market share gains and margin boost January trading statement Retail Gear4music s (G4M) Christmas trading statement shows it continuing to take share in its niche markets to generate
More information2017 INVESTOR PRESENTATION SEPTEMBER 2017
PACIFIC ENERGY LIMITED ASX : PEA 2017 INVESTOR PRESENTATION SEPTEMBER 2017 Important Notice and Disclaimer This presentation has been prepared by (PEA) for information purposes only. This presentation
More informationFor personal use only
Market Office Announcement ASX Limited Date: 9 November 2018 THINK CHILDCARE LIMITED ( TNK ) ACQUIRES 5 CHILDCARE CENTRES AND REDUCES YEAR ON YEAR OCCUPANCY GAP TO 0.5% TNK has contracted to acquire five
More informationInsurance Brokers SECTOR REPORT. Solid Hold. -4% Jun-12. Dec-12. Mar-13. Sep-13. Sep-12. Jun-13. Source: APRA, Baillieu Holst estimates
11 May 2018 RECOMMENDATIONS AUB Group (AUB) Rating HOLD Risk Low Price Target $14.50 Share Price $14.17 Steadfast Group (SDF) Rating HOLD Risk Low Price Target $2.80 Share Price $2.88 RESEARCH ANALYST
More informationBUY SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS
BUY 0.11 0.39 0.69 SHARE PRICE CASH EARNINGS ($M) COMPANY DATA & RATIOS CONTENTS Competitors Products Sales channels Pricing Model INVESTMENT THESIS COMPANY OVERVIEW INDUSTRY OVERVIEW COMPETITORS BOARD
More information2017 AGM PRESENTATION NOVEMBER 2017
PACIFIC ENERGY LIMITED ASX : PEA 2017 AGM PRESENTATION NOVEMBER 2017 Important Notice and Disclaimer This presentation has been prepared by (PEA) for information purposes only. This presentation is not
More informationContango MicroCap Ltd (CTN)
Contango MicroCap Ltd (CTN) Listed Managed Investments June 2013 Quarterly Review WHO IS IIR? Independent Investment Research, IIR, is an independent investment research house based in Australia and the
More informationFor personal use only
GENERATION HEALTHCARE REIT (ASX CODE: GHC) 2013 QUEENSLAND CONFERENCE 9 OCTOBER 2013 generationreit.com.au AGENDA Who/what is Generation Healthcare The Healthcare Sector A Snap shot Why Healthcare property
More informationVICTORIAN BUILDING & CONSTRUCTION INDUSTRY OUTLOOK
VICTORIAN BUILDING & CONSTRUCTION INDUSTRY OUTLOOK MARCH 2017 QUARTERLY UPDATE 15 JUNE 2017 PREPARED FOR THE MASTER BUILDERS ASSOCIATION OF VICTORIA STAFF RESPONSIBLE FOR THIS REPORT WERE: Director Senior
More information2016 FINANCIAL YEAR RESULTS PRESENTATION
2016 FINANCIAL YEAR RESULTS PRESENTATION 22 August 2016 www.industriareit.com.au ASX CODE: IDR Agenda 01 Highlights and Investment Proposition 02 Financial results 03 Portfolio performance 04 Capital management
More informationMATELAN Research. InVision 49.0 Buy. Excellent margin trend in Prelims. Update Note. 24 February Company / Sector Fair Value Recommendation
Update Note Price as of 21/02/13: 4 24 February 2014 Company / Sector Fair Value Recommendation InVision 49.0 Buy Technology: Cloud Computing ( 34) (Buy) Excellent margin trend in Prelims Share price performance
More informationOVERVIEW 1H17 RESULTS
CLICK 1H 2017 TO EDIT RESULTS MASTER TITLE 6 MONTHS ENDED 31 STYLE DECEMBER 2016 OVERVIEW 2 FINANCIAL SUMMARY Group Underlying Reported 1H 2017 1H 2016 1H 2017 1H 2016 Revenue 808.7 794.3 808.7 814.1 EBIT
More informationASX Announcement (ASX: PRY)
ASX Announcement (ASX: PRY) ASX Limited Market Announcements Office Exchange Centre Level 4, 20 Bridge Street Sydney NSW 2000 ACN 064 530 516 REGISTERED OFFICE: LEVEL 6 203 PACIFIC HIGHWAY ST LEONARDS
More informationCentrale del Latte d'italia
Centrale del Latte d'italia Sales improvement FY17 results Food & beverages Centrale del Latte d Italia s (CLI) price increases, implemented during H1, continue to drive revenue growth, with total revenue
More informationWisr Ltd. New products to underpin growth
Wisr Ltd Company Update New products to underpin growth Wisr Limited (WZR.AX) is an online consumer lending platform focused on financial wellness and competing in the rapidly growing marketplace lending
More informationFor personal use only
Affinity Education Group (ASX:AFJ) Morgans Conference 10 October 2014 Disclaimer This presentation contains general information in summary form which is current as at 10 October 2014. It presents financial
More informationAdvanced Vision Techn Buy
16/9/13 16/11/13 16/1/14 16/3/14 16/5/14 16/7/14 16/9/14 16/11/14 16/1/15 16/3/15 16/5/15 16/7/15 MATELAN Research Update Note Closing price as of 13/8/15: 9.16 14 August 215 Company / Sector Fair Value
More informationTabcorp Holdings Limited 2015/16
Tabcorp Holdings Limited ABN 66 063 780 709 2015/16 Full Year Results Presentation 4 August 2016 Draft version 15 (01-08-13) FY16 overview Statutory results NPAT $169.7m, down 49.3% EPS 20.4 cents per
More informationBDI BioEnergy Internat Buy
13/08/12 13/10/12 13/12/12 13/02/13 13/04/13 13/06/13 13/08/13 13/10/13 13/12/13 13/02/14 13/04/14 13/06/14 13/08/14 MATELAN Research Update Note Price as of 13/08/14: 10.29 14 August 2014 Company / Sector
More informationTXT e-solutions. Strong cash flow supports dividend boost. PACE acquisition boosts FY16 performance. Minor changes to earnings forecasts
TXT e-solutions Strong cash flow supports dividend boost FY16 results Software & comp services FY16 results confirmed that the PACE acquisition has been successfully integrated and TXT Next continues to
More informationBROKER PRESENTATION JUNE 2017
PACIFIC ENERGY LIMITED ASX : PEA BROKER PRESENTATION JUNE 2017 Important Notice and Disclaimer This presentation has been prepared by (PEA) for information purposes only. This presentation is not a product
More informationCodan Limited (ASX: CDA)
Codan Limited (ASX: CDA) 1H18 Results March 2018 WHO IS IIR?, IIR, is an independent investment research house based in Australia and the United States. IIR specialises in the analysis of high quality
More informationPacific Energy (PEA)
01 December 2017 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk High Price Target $0.69 Share Price $0.58 SNAPSHOT Monthly Turnover $5.6mn Market Cap $223mn Shares Issued 371.8mn 52-Week High $0.77 52-Week
More informationStock Focus. Pioneer Credit (PNC) Tuesday, 12 April 2016
Stock Focus Pioneer Credit (PNC) Tuesday, 12 April 2016. $2.03 $2.48 $1.69 Share Price $2.82 Positive Neutral Negative Trading Data Last Price $1.70 12 month range $1.53 - $1.85 Market Cap $78m Free Float
More informationAcquisition of European herbicide product portfolio from FMC
Acquisition of European herbicide product portfolio from FMC 8 November 2017 Important notice and disclaimer This presentation has been prepared by Nufarm Limited ACN 091 2 12 ( Nufarm" or the "Company").
More informationUBS Australasia conference. Ian Kadish (MD & CEO) 13 November 20
UBS Australasia conference Ian Kadish (MD & CEO) 13 November 20 Integral Diagnostics is a leading Diagnostic Imaging business in Victoria, Queensland and Western Australia Long history in each respective
More informationGenex Power (GNX) COMPANY REPORT. NAIF lined up for Stage 2
21 June 2018 INTERNAL ONLY RECOMMENDATIONS Rating BUY Risk Speculative Price Target $0.37 Share Price $0.31 SNAPSHOT Monthly Turnover $2.5mn Market Cap $91mn Shares Issued 303.9mn 52-Week High $0.43 52-Week
More informationFY 2018 RESULTS YEAR ENDED 30 JUNE 2018
FY 2018 RESULTS YEAR ENDED 30 JUNE 2018 PRIMARY S VISION 2 EVENT TITLE TEXT HERE PRIMARY S VISION» Healthcare in Australia largely unchanged for decades» At a watershed with costs, technology and choice
More informationSales increased 8.1% to $128.0m (HY17: $118.4m)
Nick Scali Limited NCK.ASX HY18 Results Presentation 7th February 2018 Key Highlights Sales increased 8.1% to $128.0m (HY17: $118.4m) Sales Like for like sales growth of +2.6% for Nick Scali Furniture
More informationWestoz Investment Company. October 2018
Westoz Investment Company October 2018 Disclaimer Disclaimer & Disclosure Westoz Investment Company Limited ACN 113 332 942 (WIC) and Westoz Funds Management Pty Ltd (WFM) AFSL 85607, their related entities
More informationTOURISM HOLDINGS LTD FY16 INTERIM RESULTS PRESENTATION. 23 February 2016
TOURISM HOLDINGS LTD FY16 INTERIM RESULTS PRESENTATION 23 February 2016 $M H1 FY16 Highlights Revenue $134M up 20% Earnings before interest and tax* $15.0M up 42% Net profit after tax $8.2M up 45% H1 EBIT
More informationAppen Limited (APX-AU) 29 August 2017
Appen Limited (APX-AU) 29 August 2017 Pricing in another Upgrade Marketperform Adam Dellaverde adamd@taylorcollison.com.au +618 8217 3923 +6403 013 032 Summary Market capitalisation ($m) $438.7 Share price
More informationHY18 RESULTS PRESENTATION FEBRUARY 2018
PACIFIC ENERGY LIMITED ASX : PEA HY18 RESULTS PRESENTATION FEBRUARY 2018 Important Notice and Disclaimer This presentation has been prepared by (PEA) for information purposes only. This presentation is
More informationTXT e-solutions. Steady growth in Q3. Growth for both businesses in Q3. Outlook and changes to forecasts
TXT e-solutions Steady growth in Q3 Q3 results Software & comp services TXT reported a strong set of results for Q316: organic growth in both businesses was boosted by the contribution from April s acquisition
More informationAffinity Education Group. Market Update presentation
Affinity Education Group Market Update presentation 7 July 2015 FY15 Highlights Earnings Guidance Underlying EBITDA forecast for H1 of $7.5m to $8.5m Underlying EBITDA forecast for FY15 of $27m to $32m
More informationCircle Property. Lifting estimates again. Revaluation gains and strong rent growth. Upside potential from refurbished assets
Circle Property Lifting estimates again Review of trading update Real estate Circle will publish results for the year to 31 March 2018 in June but recent updates show further strong momentum. Ongoing asset
More informationEBOS Group Ltd. For personal use only. Results presentation Financial Year ended 30 June August 2016
EBOS Group Ltd Results presentation Financial Year ended 30 June 2016 Patrick Davies John Cullity Chief Executive Officer Chief Financial Officer 25 August 2016 Disclaimer The information in this presentation
More informationCapital raising. May Doug Rathbone Managing Director and Chief Executive Officer. Kevin Martin Chief Financial Officer
May 15 2009 Capital raising Doug Rathbone Managing Director and Chief Executive Officer Kevin Martin Chief Financial Officer Robert Reis Group GM - Corporate Strategy & External Affairs Important information
More informationConsolidated Operations Group (COG)
Consolidated Operations Group (COG) 10 April 2018 Outperform Upgrade to OUTPERFORM - Inflection point nearing $0.10 Jason Palmer jpalmer@taylorcollison.com.au +618 8217 3965 Summary (AUD) Market Capitalisation
More informationBendigo and Adelaide Bank Limited (Bendigo Bank)
(Bendigo Bank) Executive summary (Bendigo Bank) is a regional bank that specialises in retail banking with a focus on rural communities. It also owns Rural Bank and Delphi Bank and operates the margin
More informationFor personal use only. JB Hi-Fi Limited. HY17 Results Presentation
JB Hi-Fi Limited HY7 Results Presentation 3 5 FEBRUARY AUGUST 06 07 PAGE Agenda. Group Performance Overview. JB HI-FI 3. The Good Guys 4. Stores 5. Group Balance Sheet and Cash Flow 6. Outlook Richard
More informationGenworth Mortgage Insurance Australia
Genworth Mortgage Insurance Australia 1Q 2015 Financial results presentation 29 April 2015 2015 Genworth Mortgage Insurance Australia Limited. All rights reserved. Disclaimer This presentation contains
More informationartnet For art's sake FY15: Art fair partnerships and forays to China Intended reporting change Valuation: Overshadowed Q1 figures
artnet For art's sake Q1 figures Media The online element of the international fine art market has continued to appreciate in Q115, despite a duller auction market, and artnet s News platform has been
More informationSG Fleet Group % growth in FY17. Earnings and target price revision. Price catalyst. Catalyst: Results and contract wins.
AUSTRALIA SGF AU Price (at 07:57, 27 Oct 2016 GMT) Outperform A$3.85 Valuation - PER A$ 3.92-4.18 12-month target A$ 4.37 12-month TSR % +18.1 Volatility Index Medium GICS sector Commercial & Professional
More informationDICKER DATA LIMITED ANNUAL RESULTS
DICKER DATA LIMITED ANNUAL RESULTS ANOTHER YEAR OF GROWTH DESPITE SOFT MARKET CONDITIONS Newport Capital produced this report to provide Australian wholesale clients and sophisticated investors with an
More informationFY2015 Annual Results August Brett McKeon - CEO David Bailey - CFO
FY2015 Annual Results August 27 2015 Brett McKeon - CEO David Bailey - CFO FY2015 Financial Results Highlights Delivery on FY15 Prospectus forecasts Pro forma NPAT $19.3 million up 8.4% against IPO forecast
More informationNoni B (NBL) SFH acquisition could be up to 60% EPS accretive. Key points. Risks and catalysts
Date Theme Company Update Company Noni B (NBL) SFH acquisition could be up to 6 EPS accretive Press reports today (Australian) suggest Noni B is a potential acquirer of Specialty Fashion Group (SFH), in
More informationEclipx Group. Highlights its funding flexibility A$3.77 AUSTRALIA. Event. Impact. Earnings and target price revision.
AUSTRALIA ECX AU Price (at 02:49, 15 Dec 2016 GMT) Outperform A$3.77 Valuation - PER A$ 3.53-3.78 12-month target A$ 4.22 12-month TSR % +16.3 Volatility Index Low/Medium GICS sector Diversified Financials
More informationFor personal use only. Investor Presentation Bravura Solutions Limited
Investor Presentation Bravura Solutions Limited Tony Klim CEO 27 April 2017 The information contained in this document (including this notice) or discussed at this presentation (collectively, the Presentation)
More informationAffinity Education Group. Half Year Results
Affinity Education Group Half Year Results 29 August 2014 Disclaimer This presentation contains general information in summary form which is current as at 29 August 2014. It presents financial information
More informationContango MicroCap Ltd (CTN)
Contango MicroCap Ltd (CTN) Listed Managed Investments June 2014 Quarterly Review WHO IS IIR? Independent Investment Research, IIR, is an independent investment research house based in Australia and the
More informationGenworth Mortgage Insurance Australia
Genworth Mortgage Insurance Australia 1Q 2016 Financial results presentation 29 April 2016 2016 Genworth Mortgage Insurance Australia Limited. All rights reserved. Disclaimer This presentation contains
More informationFULL YEAR RESULTS 2016
FULL YEAR RESULTS 2016 Disclaimer The material in this presentation is a summary of the results of nib holdings limited (nib) for the 12 months ended 30 June 2016 and an update on nib s activities and
More informationFor personal use only
Investor presentation Acquisition of Autopia Group 4 July 2016 PAGE 0 Acquisition of 100% of Autopia to grow Smartgroup s leasing portfolio and expand client base in corporate segment Autopia overview
More information1H18 results. Dr. Ian Kadish (MD & CEO) Anne Lockwood (CFO) 19 January 2018
1H18 results Dr. Ian Kadish (MD & CEO) Anne Lockwood (CFO) 19 January 2018 Today s presenters Dr. Ian Kadish Managing Director and Chief Executive Officer Joined Integral Diagnostics in May 2017 Has held
More informationFor personal use only. Beacon Lighting Group Limited RESULTS PRESENTATION F Y 20 14
For personal use only Beacon Lighting Group Limited RESULTS PRESENTATION F Y 20 14 AGENDA 1. BACKGROUND 2. RESULTS OVERVIEW 3. TRADING PERFORMANCE 4. CASH FLOW, BALANCE SHEET, DIVIDEND 5. GROWTH STRATEGY
More informationFOR THE HALF-YEAR ENDED 28 FEBRUARY Bank of Queensland Limited ABN AFSL No
FOR THE HALF-YEAR ENDED 28 FEBRUARY 2017 Bank of Queensland Limited ABN 32 009 656 740. AFSL No 244616. JON SUTTON Managing Director & CEO ANTHONY ROSE Chief Financial Officer JON SUTTON Managing Director
More informationAPN Outdoor Group (APO)
26 June 2018 INTERNAL ONLY RECOMMENDATIONS Rating HOLD Risk Medium Price Target $6.70 Share Price $6.45 SNAPSHOT Monthly Turnover $323.7mn Market Cap $1,069mn Shares Issued 167.0mn 52-Week High $6.70 52-Week
More informationHelma Eigenheimbau. Scale research report - Update. Market bottlenecks limiting momentum. H117 results showing moderate growth
Scale research report - Update Helma Eigenheimbau Market bottlenecks limiting momentum Home builders 14 September 2017 Price 41.60 Market cap 166m Helma s H117 results confirmed the anticipated slowdown
More informationFor personal use only
Results Presentation First Half Financial Results 31 December 2018 www.pscgroup.com.au Highlights 1 50 Revenue ($m) Revenue of $40.8m up 42% on 1HFY18 ($28.8m) Underlying EBITDA of $3.1m up 46.1% on 1HFY18
More informationDr. Lal PathLabs Limited (DLPL) Q1 FY19 Results Presentation August 10, 2018
Dr. Lal PathLabs Limited (DLPL) Q1 FY19 Results Presentation August 10, 2018 Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials,
More informationPaysafe Group. Growth normalises. Growth moderates in H117. Pro forma financials show potential impact of deals
Paysafe Group Growth normalises H117 results Software & comp services Paysafe s H117 results show that organic constant currency growth is moderating to low double-digit rates, after an exceptional period
More informationFor personal use only
Ramsay Health Care Limited MACQUARIE SECURITIES AUSTRALIA CONFERENCE 2015 6 May 2015 Christopher Rex, Managing Director AGENDA 1. Ramsay Health Care Overview 2. Group Financial Highlights for the six months
More informationAtCor Medical Holdings Limited (ACG)
Volume (million) AtCor Medical Holdings Limited (ACG) 30 March 2015 Speculative Buy Value Creation Ahead Post CPT1 Code Award $0.20 Marcus Hamilton mhamilton@taylorcollison.com.au +61 2 9210 1317 Summary
More informationASX ANNOUNCEMENT DATE: 22 February 2017 Attached is the Presentation regarding Pact s Half year Financial Results for the half year ended 31 December 2016. The Presentation will occur at 10am (Melbourne
More informationDr. Lal PathLabs Limited (DLPL) Q3 & 9M FY18 Results Presentation February 08, 2018
Dr. Lal PathLabs Limited (DLPL) Q3 & 9M FY18 Results Presentation February 08, 2018 Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation
More informationFor personal use only
FY16 RESULTS BRIEFING H U G H M A R K S C H I E F E X E C U T I V E O F F I C E R G R E G B A R N E S C H I E F F I N A N C I A L O F F I C E R M I C H A E L S T E P H E N S O N C H I E F S A L E S O F
More informationFY2014 Full year results
FY2014 Full year results Peter Watson CEO I Managing Director Ian Poole Chief Financial Officer 28 August 2014 FY2014 year in review Resources capital expenditure conditions subdued Strong underlying result
More informationMorgan Stanley Australian Emerging Companies Conference
Morgan Stanley Australian Emerging Companies Conference John Livingston (CEO) Craig Bremner (CFO) 15 June 2016 ATTRACTIVE BUSINESS MODEL 1 IDX BUSINESS MODEL The combination of IDX's referrers, sites,
More information